Read more
"The United States' decentralized, largely privatized, and commerce-driven healthcare system is undergoing a shift to personal genome medicine. This change is charged by ongoing progress in biotech and genomic research and development. This book draws from U.S. medicine's past and present to address its emerging personal genome medicine future"--
List of contents
Prologue: revolution, transition and transformation; 1. Medical profession sovereignty to protect and promote the science and evidence base of US medicine; 2. US integration of government, academia and industry: a catalyst for science-technology revolutions; 3. The proliferation of US Direct-to-Consumer (DTC) and Direct-to-Physician (DTP) biopharmaceutical marketing; 4. The evolution of consumer genetic testing services from Oncormed, Inc. to 23andMe Holding Co.; 5. Vulnerability of the science and evidence base of US medicine; 6. A warning label for commercial Direct-to-Consumer (DTC) genetics; 7. Protecting and promoting the evidentiary-science base of Personal Genome Medicine (PGM); Epilogue: the personal genome future of US medicine.
About the author
Michael J. Malinowski is the Ernest R. and Iris M. Eldred Endowed Professor of Law and the Lawrence B. Sandoz Jr. Endowed Professor of Law at the Paul M. Hebert Law Center, Louisiana State University. He has published extensively on biotechnology research and development (R&D), health care, and bioethics.
Summary
The United States' decentralized, largely privatized, and commerce-driven healthcare system is undergoing a shift to personal genome medicine. This change is charged by ongoing progress in biotech and genomic research and development. This book draws from U.S. medicine's past and present to address its emerging personal genome medicine future.
Foreword
Draws from the past and present of medicine in the U.S. to address the emerging future of personal genome medicine.
